| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 453 | 2018 |
| Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 … DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ... The Lancet Oncology 20 (12), 1730-1739, 2019 | 285 | 2019 |
| Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ... Nature Communications 12 (1), 184, 2021 | 100 | 2021 |
| Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse S Taavitsainen, N Engedal, S Cao, F Handle, A Erickson, S Prekovic, ... Nature communications 12 (1), 5307, 2021 | 67 | 2021 |
| Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ... Clinical Cancer Research 26 (5), 1114-1125, 2020 | 66 | 2020 |
| Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ... European urology 78 (6), 834-844, 2020 | 64 | 2020 |
| Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy DJ Woodcock, E Riabchenko, S Taavitsainen, M Kankainen, G Gundem, ... Nature communications 11 (1), 5070, 2020 | 52 | 2020 |
| Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition M Annala, S Taavitsainen, DJ Khalaf, G Vandekerkhove, K Beja, J Sipola, ... Clinical Cancer Research 27 (16), 4610-4623, 2021 | 51 | 2021 |
| Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, ... Annals of Oncology 32 (7), 896-905, 2021 | 48 | 2021 |
| Evaluation of commercial circulating tumor DNA test in metastatic prostate cancer S Taavitsainen, M Annala, E Ledet, K Beja, PJ Miller, M Moses, M Nykter, ... JCO precision oncology 3, 1-9, 2019 | 44 | 2019 |
| Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression S Cao, JR Wang, S Ji, P Yang, Y Dai, S Guo, MD Montierth, JP Shen, ... Nature biotechnology 40 (11), 1624-1633, 2022 | 40 | 2022 |
| Interleukin 10 mutant zebrafish have an enhanced interferon gamma response and improved survival against a Mycobacterium marinum infection SKE Harjula, MJT Ojanen, S Taavitsainen, M Nykter, M Rämet Scientific reports 8 (1), 10360, 2018 | 38 | 2018 |
| HSD3B1 (1245A> C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two … DJ Khalaf, IM Aragón, M Annala, R Lozano, S Taavitsainen, D Lorente, ... Annals of Oncology 31 (9), 1186-1197, 2020 | 26 | 2020 |
| Frequent mutation of the FOXA1 untranslated region in prostate cancer M Annala, S Taavitsainen, G Vandekerkhove, JVW Bacon, K Beja, KN Chi, ... Communications biology 1 (1), 122, 2018 | 26 | 2018 |
| Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response K Kukkonen, S Taavitsainen, L Huhtala, J Uusi-Makela, KJ Granberg, ... Cancers 13 (13), 3325, 2021 | 17 | 2021 |
| A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC) KN Chi, S Taavitsainen, N Iqbal, C Ferrario, M Ong, D Wadhwa, SJ Hotte, ... Annals of Oncology 29, viii271-viii272, 2018 | 11 | 2018 |
| Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity K Ketola, H Kaljunen, S Taavitsainen, R Kaarijärvi, E Järvelä, ... Cancer research 81 (19), 4901-4909, 2021 | 7 | 2021 |
| Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine A Nurminen, S Jaatinen, S Taavitsainen, G Högnäs, T Lesluyes, ... Genome medicine 15 (1), 82, 2023 | 3 | 2023 |
| Combined longitudinal clinical and autopsy phenomic assessment in lethal metastatic prostate cancer: recommendations for advancing precision medicine J Jasu, T Tolonen, ES Antonarakis, H Beltran, S Halabi, MA Eisenberger, ... European Urology Open Science 30, 47-62, 2021 | 3 | 2021 |
| Fanconi anemia pathway regulation by FANCI in prostate cancer H Kaljunen, S Taavitsainen, R Kaarijärvi, E Takala, V Paakinaho, ... Frontiers in Oncology 13, 1260826, 2023 | 2 | 2023 |
